Press Releases Jun 06, 2023 Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference May 23, 2023 Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use May 11, 2023 Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases View all press releases Presentations & Events Goldman Sachs Annual Global Healthcare Conference Jun 12, 2023 at 5:00 PM EDT Listen to webcast View all presentations & events Form 8937 View Form 8937 - September 30, 2015 View Form 8937
May 23, 2023 Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use
May 11, 2023 Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases